These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22180526)

  • 1. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.
    Haas DW; Kuritzkes DR; Ritchie MD; Amur S; Gage BF; Maartens G; Masys D; Fellay J; Phillips E; Ribaudo HJ; Freedberg KA; Petropoulos C; Manolio TA; Gulick RM; Haubrich R; Kim P; Dehlinger M; Abebe R; Telenti A;
    HIV Clin Trials; 2011; 12(5):277-85. PubMed ID: 22180526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.
    Godfrey C; Thigpen MC; Crawford KW; Jean-Phillippe P; Pillay D; Persaud D; Kuritzkes DR; Wainberg M; Raizes E; Fitzgibbon J
    J Infect Dis; 2017 Dec; 216(suppl_9):S798-S800. PubMed ID: 28973412
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV and pharmacogenomics in 2007.
    Khoo S
    Pharmacogenomics; 2007 Jan; 8(1):25-7. PubMed ID: 17187506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction of HIV drug-resistance testing in clinical practice.
    Rodríguez-Rosado R; Briones C; Soriano V
    AIDS; 1999 Jun; 13(9):1007-14. PubMed ID: 10397528
    [No Abstract]   [Full Text] [Related]  

  • 5. Possibility of HIV-1 resistance mutations in cerebrospinal fluid from persons receiving suppressive therapy.
    Seligman SJ
    J Infect Dis; 2011 Jul; 204(1):174; author reply 174-5. PubMed ID: 21628673
    [No Abstract]   [Full Text] [Related]  

  • 6. Growing number of drug resistant strains dominates at retroviruses conference. Drug resistance is an 800-pound gorilla.
    AIDS Alert; 2005 May; 20(5):49, 51-3. PubMed ID: 15912613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Viroseq-HIV version 2 for HIV drug resistance.
    Mukaide M; Sugiura W; Matuda M; Usuku S; Noguchi Y; Suzuki K; Kawata K; Ito A; Sagara H; Yamada K; Kondo M; Imai M
    Jpn J Infect Dis; 2000 Oct; 53(5):203-5. PubMed ID: 11135705
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview on HIV-1-related drug resistance: from theory to clinical practice.
    Moroni M; Balotta C; Rusconi S
    J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):15-8. PubMed ID: 9689573
    [No Abstract]   [Full Text] [Related]  

  • 9. Update of the drug resistance mutations in HIV-1: Spring 2008.
    Johnson VA; Brun-Vezinet F; Clotet B; Günthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
    Top HIV Med; 2008; 16(1):62-8. PubMed ID: 18441382
    [No Abstract]   [Full Text] [Related]  

  • 10. Genotyping HIV isolates paves the way to effective treatment regimes.
    Sansom C
    Mol Med Today; 1999 Oct; 5(10):417. PubMed ID: 10498906
    [No Abstract]   [Full Text] [Related]  

  • 11. Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1.
    Kosakovsky Pond SL; Smith DM
    Clin Infect Dis; 2009 May; 48(9):1306-9. PubMed ID: 19331584
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection and significance of minority quasispecies of drug-resistant HIV-1.
    Metzner KJ
    J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210
    [No Abstract]   [Full Text] [Related]  

  • 13. Residual HIV-1 disease in the era of highly active antiretroviral therapy.
    Pomerantz RJ
    N Engl J Med; 1999 May; 340(21):1672-4. PubMed ID: 10341281
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of the oral HIV/AIDS Research Alliance Program.
    Shiboski CH; Webster-Cyriaque JY; Ghannoum M; Greenspan JS; Dittmer D;
    Adv Dent Res; 2011 Apr; 23(1):28-33. PubMed ID: 21441477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of drug resistance-related mutations among HIV-1s in Japan.
    Sugiura W; Matsuda M; Abumi H; Yamada K; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takada N; Kakishita E; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Feb; 52(1):21-2. PubMed ID: 10808258
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 17. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 18. Indication for increasing prevalence of resistance mutations for protease inhibitors in therapy-naive HIV-1-positive German patients.
    Dietrich U; Raudonat I; Wolf E; Jäger H; Husak R; Orfanos CE; Knickmann M; Knechten H; von Briesen H; Ruppach H; Immelmann A
    AIDS; 1999 Nov; 13(16):2304-5. PubMed ID: 10563717
    [No Abstract]   [Full Text] [Related]  

  • 19. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 20. Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response.
    Derdelinckx I; Van Laethem K; Maes B; Schrooten Y; De Wit S; Florence E; Fransen K; Ribas SG; Marissens D; Moutschen M; Vaira D; Zissis G; Van Ranst M; Van Wijngaerden E; Vandamme AM
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1664-6. PubMed ID: 15577426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.